B2M and leukemia: The results showed that β2m KD led to decreased MHC-I molecule levels (Fig. 6H and I) with decreased CTL killing of leukemia cells (Fig. 6J), suggesting that increased PSMB10 results in leukemia cell resistance to CTL-mediated killing through the direct interaction and ubiquitinated degradation of MHC-I protein.